



Supplement Figure 4

Supplement Figure 4a. DAA treatment effect on blood ALT/AST trajectory for persons with HIV/HCV coinfection, the HIV Outpatient Study, 2010-2020




Note: Index date refers to date of DAA prescription for DAA-treated group and propensity score matched pseudo date of DAA prescription for DAA-naïve group, respectively.

Supplement Figure 4b. DAA treatment effect on blood platelet count trajectory for persons with HIV/HCV coinfection, the HIV Outpatient Study, 2010-2020



Note: Index date refers to date of DAA prescription for DAA-treated group and propensity score matched pseudo date of DAA prescription for DAA-naïve group, respectively.

Supplement Figure 4c. DAA treatment effect on Fib-4 score trajectory for persons with HIV/HCV coinfection, the HIV Outpatient Study, 2010-2020



Note: Index date refers to date of DAA prescription for DAA-treated group and propensity score matched pseudo date of DAA prescription for DAA-naïve group, respectively. Some extreme Fib-4 values suppressed.